TERN vs. INZY, AQST, ENTA, ENZ, NXTC, MORF, SUPN, AVDL, SYRE, and XNCR
Should you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Inozyme Pharma (INZY), Aquestive Therapeutics (AQST), Enanta Pharmaceuticals (ENTA), Enzo Biochem (ENZ), NextCure (NXTC), Morphic (MORF), Supernus Pharmaceuticals (SUPN), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), and Xencor (XNCR). These companies are all part of the "medical" sector.
Inozyme Pharma (NASDAQ:INZY) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
Inozyme Pharma currently has a consensus target price of $16.40, suggesting a potential upside of 254.21%. Terns Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 102.80%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Inozyme Pharma is more favorable than Terns Pharmaceuticals.
Inozyme Pharma has higher earnings, but lower revenue than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Terns Pharmaceuticals had 1 more articles in the media than Inozyme Pharma. MarketBeat recorded 2 mentions for Terns Pharmaceuticals and 1 mentions for Inozyme Pharma. Terns Pharmaceuticals' average media sentiment score of 1.87 beat Inozyme Pharma's score of 0.96 indicating that Inozyme Pharma is being referred to more favorably in the media.
88.3% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. 11.2% of Inozyme Pharma shares are owned by company insiders. Comparatively, 15.1% of Terns Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Inozyme Pharma received 1 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 81.82% of users gave Inozyme Pharma an outperform vote while only 58.33% of users gave Terns Pharmaceuticals an outperform vote.
Inozyme Pharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500.
Inozyme Pharma's return on equity of -35.54% beat Terns Pharmaceuticals' return on equity.
Summary
Inozyme Pharma beats Terns Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Terns Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Terns Pharmaceuticals Competitors List
Related Companies and Tools
